Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Unknown

Conditions: Diffuse Diseases

Treatments: Device: MRI 3 T; Biological: blood sample; Device: MRI 7T

Study type: Interventional

Funder types: Other

Identifiers

NCT03039166

2016-46 (Other Identifier)

2016-A01785-46

Details and patient eligibility

About

the investigators hypothesize that hub alteration occurs both in diffuse diseases (MS, AD) as well as in more 'network specific' diseases (Parkinson, ALS, Epilepsy). This could impact on functional dysfunction not directly related to each disease, but that could induce common syndrome such as cognitive impairment observed in Parkinson, partial epilepsy or ALS.

The objective here is to test this hypothesis and provides better understandings on pathophysiological processes affecting those highly connected regions in 'diffuse' and 'focal' neurological diseases.

The ultimate goal is to identify new clinical targets for trans-nosological approaches (DBS, cognitive rehabilitation ...).

Practically, the investigators will explore 200 patients classified in 5 cohorts of 40 patients suffering for MS, AD, Parkinson, ALS, Epilepsy, using the last advanced methods to assess structural and functional brain connectivity implemented on the human 7T MR scanner equipping the CEMEREM (CHU Timone, Marseille, only 50 similar MR scanners worldwide).

In addition to high resolution diffusion MRI and rs-fMRI, metabolic and ionic (sodium) mapping will complement the MR protocol to characterize the pathophysiological processes of hub injury. Sixty healthy controls will also be explored wih the same protocol for normal database.

The proposal aims at characterizing and comparing from a morphological-functional point of view, the hub regions of patients suffering from these five diseases, to demonstrate the pertinence to preserve hub integrity as a major therapeutic target whatever the disease.

Enrollment: 260 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Person female or male, more than 18-year-old,
• Person presenting unchecked general disease such as severe cancer, autoimmune disease, hepatic insufficiency, severe or untreated, shady arterial high blood pressure of the conduction or the disorder of the rhythm
• Person presenting chronic psychiatric disease, insane syndrome.
• Person presenting contraindication to the realization of an examination by MRI (metallic claustrophobia, foreign body, pacemakers),
• Person benefiting from a social security cover,
• Person having read, understood and signed an informed consent after information

Exclusion criteria

• Claustrophobia,
• Metallic foreign bodies,
• Pacemakers,
• Severe renal insufficiency

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

260 participants in 6 patient groups

parkinson

Experimental group

Treatment:

Device: MRI 3 T

Device: MRI 7T

partial epilepsy

Experimental group

Treatment:

Device: MRI 3 T

Device: MRI 7T

alzheimer disease

Experimental group

Treatment:

Device: MRI 3 T

Device: MRI 7T

multiple sclerosis

Experimental group

Treatment:

Device: MRI 3 T

Device: MRI 7T

Biological: blood sample

amyotrophic lateral sclerosis

Experimental group

Treatment:

Device: MRI 3 T

Device: MRI 7T

healthy control patients

Active Comparator group

Treatment:

Device: MRI 3 T

Device: MRI 7T